Furthermore, these results suggest that loss of LKB1 signaling in breast cancer reduces the ability of cells to overcome metabolic stress; however, treatments that target aberrant glycolysis and mTOR signaling drive the cells to overcome metabolic stress, ultimately resulting in decreased tumourigenesis, as observed in our pre-clinical study (Fig. 3). This evidence concerns the gene STK11 and breast cancer.